secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001104659-24-128517
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path receives Nasdaq bid-price deficiency notice; shareholders OK reverse split
--------------------------------------------------------------------------------

- Nasdaq letter Dec 12, 2024: closing bid below $1 for 30 straight days; 180 days until June 10, 2025 to comply.
- Stockholders approved reverse stock split up to 1-for-30 to potentially cure deficiency.
- Approved increase in 2022 Stock Incentive Plan shares by 1,200,000 to total 1,265,000 shares.
- Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2024.
- All five director nominees elected with over 80% of votes cast for each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/0001104659-24-128517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/tm2431094d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-128517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer